مباشر

Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN Thermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance 10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.com Eli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord Pharma Endpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for Voyxact AgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.st Boston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDevice Charles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWS Endpoints NewsActing FDA chief isn't interested in permanent role Clinical OMICsPost-Stroke Arm Immobility Improved with Spinal Cord Stimulation Lonza NewsStipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies - Genetic Engineering and Biotechnology News

الأرشيف

الأحدث الأقدم مسح

@BioPharma Dive

الإجمالي 509

المصدر BioPharma Dive

بحث --

BioPharma Dive ٥ مايو ٢٠٢٦

Cytokinetics heart drug scores in closely watched trial

BioPharma Dive ٥ مايو ٢٠٢٦

Cytospire hauls in $83M for a new type of T cell engager

BioPharma Dive ٤ مايو ٢٠٢٦

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

BioPharma Dive ٤ مايو ٢٠٢٦

With $97M, Latus pursues a different kind of Huntington’s gene therapy

BioPharma Dive ٤ مايو ٢٠٢٦

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

BioPharma Dive ٤ مايو ٢٠٢٦

What is your AI drug repurposing strategy missing?

BioPharma Dive ١ مايو ٢٠٢٦

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

BioPharma Dive ١ مايو ٢٠٢٦

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

BioPharma Dive ١ مايو ٢٠٢٦

Moderna sees revenue bump from international COVID vaccine sales

BioPharma Dive ١ مايو ٢٠٢٦

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

BioPharma Dive ١ مايو ٢٠٢٦

Two biotechs raise a combined $556M in latest spurt of IPOs

BioPharma Dive ٣٠ أبريل ٢٠٢٦

Merck still sees ‘compelling’ outlook for Terns leukemia drug

BioPharma Dive ٣٠ أبريل ٢٠٢٦

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

BioPharma Dive ٣٠ أبريل ٢٠٢٦

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

BioPharma Dive ٣٠ أبريل ٢٠٢٦

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

BioPharma Dive ٢٩ أبريل ٢٠٢٦

Teva nabs experimental Tourette drug in $700M Emalex buyout

BioPharma Dive ٢٩ أبريل ٢٠٢٦

Chiesi to buy KalVista in $1.9B deal for rare disease drug

BioPharma Dive ٢٩ أبريل ٢٠٢٦

FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech